Table 3 Skin and muscle sodium and water content at baseline and after 6 weeks of treatment
From: SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
| Â | Baseline | Dapagliflozin vs. baseline | Placebo vs. baseline | ||
|---|---|---|---|---|---|
X ± SD | X ± SD | p-value | X ± SD | p-value | |
Skin Na + (A.U.) | 24.5 ± 7.2 | 22.7 ± 6.4 | 0.013 | 23.8 ± 8.3 | 0.314 |
Skin H2O (A.U.) | 0.153 ± 0.06 | 0.144 ± 0.06 | 0.073 | 0.15 ± 0.07 | 0.763 |
Na + M. triceps surae (A.U.) | 20.6 ± 3.5 | 20.4 ± 3.7 | 0.801 | 20.3 ± 3.6 | 0.514 |
H2O M. triceps surae (A.U.) | 0.513 ± 0.03 | 0.513 ± 0.03 | 0.952 | 0.505 ± 0.03 | 0.014 |
Body weight (kg) | 87.6 ± 13 | 86.6 ± 13 | 0.001 | 87.6 ± 13 | 0.930 |
Urin Na + 24 h (mmol/day) | 216 ± 81 | 210 ± 17 | 0.586 | 222 ± 104 | 0.660 |